SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
China SXT Pharmaceuticals, Inc.
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026
$0.11+0.05 (+71.08%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$16,679.8888 (−100.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
China SXT Pharmaceuticals, Inc. saw revenue fall 34.6% to $1.14M over fiscal 2026.
Revenue
$1.14M
-34.6% vs. a year earlier
Operating income
-$7.12M
FY2026
EPS, diluted
-$9.13
FY2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Mar 31, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.14M
- Net income
- -$6.21M
- EPS, diluted
- -$9.13
Eleven years at a glance
Fiscal years 2016 to 2026, USD
Revenue
$1.14M-34.6% YoY
Gross profit
$248.70K-32.3% YoY
Operating income
-$7.12M
Net income
-$6.21M
EPS, diluted
-$9.13
Free cash flow
–
Reported period